Duloxetine 20mg Delayed-Release Capsules Recalled for N-Nitroso Impurity
Breckenridge Pharmaceutical is recalling 7,107 bottles of Duloxetine 20mg delayed-release capsules nationwide due to N-nitroso-duloxetine impurity exceeding FDA interim limits. No illnesses have been reported.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall for manufacturing deviations involving N-nitroso impurities exceeding recommended limits. This constitutes a risk-of-harm product category with manufacturing contamination, but no illnesses or injuries have been reported, placing it in the High-severity tier per the rubric.
Plain-English summary
Breckenridge Pharmaceutical, Inc. is recalling 7,107 bottles of Duloxetine Delayed-Release Capsules, USP, 20mg, Rx Only, due to Current Good Manufacturing Practice (CGMP) deviations related to the presence of N-nitroso-duloxetine impurity.
The recalled product is Duloxetine Delayed-Release Capsules, 20mg, distributed in 500-count bottles under NDC 51991-746-05, with Lot #220128 and expiration date 12/2024. The impurity level was found to exceed the FDA's recommended interim limit.
The product was distributed nationwide throughout the United States. The recall affects all patients who may have received bottles from this lot.
Patients should not discontinue their medication without consulting their healthcare provider. Those who have received this recalled lot should contact their pharmacy for a replacement or additional guidance.
The recalled product
- Product
- DULOXETINE (DULOXETINE HYDROCHLORIDE)
- Brand
- DULOXETINE
- Manufacturer
- Breckenridge Pharmaceutical, Inc
- Category
- Drug — Antidepressant
- Hazard
- Affected units
- 7,107
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 220128
- Exp. Date 12/2024
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · DULOXETINE
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighEnovachem duloxetine capsules exceed the nitrosamine acceptable intake limit
FDA (Drugs) · 2026-06-10
- ModerateDuloxetine Delayed-Release Capsules Recalled for Impurity Above Limit
FDA (Drugs) · 2026-05-13
- ModerateDuloxetine Delayed-Release Capsules 20 mg Recalled for Impurity
FDA (Drugs) · 2026-05-13
Same manufacturer · Breckenridge Pharmaceutical, Inc
See all →- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- HighDuloxetine delayed-release capsules recalled over a nitrosamine impurity above FDA limits
FDA (Drugs) · 2025-12-10
- HighIntelliVue MX550 patient monitors recalled over an alarm activation issue
FDA (Drugs) · 2025-12-10
- HighDuloxetine capsules recalled over nitrosamine impurity above the safety assessment limit
FDA (Drugs) · 2025-11-05
- HighDuloxetine delayed-release capsules recalled over N-nitroso-duloxetine above interim limit
FDA (Drugs) · 2025-09-17
Same hazard · nitrosamine impurity
See all →- HighCipla cinacalcet 60 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighCipla cinacalcet 30 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighCipla cinacalcet 90 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighPrazosin hydrochloride 100-count bottles recalled over nitrosamine impurity
FDA (Drugs) · 2026-04-08
- HighPrazosin hydrochloride tablets recalled over nitrosamine impurity above limits
FDA (Drugs) · 2026-04-08